HPV33 and HPV45 sublineage antigenicity defined by neutralizing antibodies elicited during natural infection.

Kazutomo Yokoya K. Panwar V. Tenet R. Hussain F. D. da Silva L. Mirabello John T. Schiller G. Clifford S. Beddows

Sep 2026 · Journal of Infectious Diseases · 0 citations

Medicine

TL;DR

A global panel of natural infection sera and relational antigenic maps is used to assess HPV33 and HPV45 neutralizing antibody specificity to inform the degree of lineage and sublineage specificity within the natural infection humoral immune response to oncogenic HPV.

DOI PubMed Semantic Scholar

View source

Similar papers

Open access Sep 2026

Epstein-Barr virus gp350 neutralizing epitopes define distinct sites of vulnerability.

Epstein-Barr virus (EBV) is a widespread human herpesvirus linked to several malignancies, yet no vaccine has been approved. Its major surface glycoprotein, gp350, mediates attachment to B cells via CR2 binding, but gp350-based vaccines have shown limited protection, raising questions about its neutralizing epitopes an...

Ge-Xin Zhao, Peng-Lin Li, Bo-Yu Yuan et al. · Cell Reports · 0 citations

Open access Aug 2026

Factors impacting protective immunity conferred by vaccination with adeno-associated virus-like particles displaying human papillomavirus L2 residues 17–36

ABSTRACT A phase I study was conducted in 20 healthy subjects with 20 µg adeno-associated virus 2 (AAV2)-like particles displaying L2 residues 17–36 of both human papillomavirus (HPV) type 16 and HPV31 (AAVLP-HPV) or placebo. AAVLP-HPV vaccination was well tolerated and induced a modest L2-specific serum antibody titer...

Jade Alvarez, Pola Olczak, Hua-Ling Tsai et al. · Journal of Virology · 0 citations

Open access Sep 2026

Heterologous Antigen Regimen and Bicistronic DNA Vaccination Targeting HPV16 E5 and E7 Oncoproteins: Immunoinformatics and Preclinical Antitumor Efficacy

Persistent infection with high-risk human papillomavirus, particularly HPV16, is a major cause of cervical cancer and orogenital malignancies. Therapeutic DNA vaccines targeting viral oncoproteins represent a promising strategy to induce antitumor immune responses. However, the impact of antigen combinations in bicistr...

Ingrid Andrêssa de Moura, Karina Mayumi Tani Bezerra de Melo, L. R. S. Leal et al. · Molecules · 0 citations

Open access Sep 2026

L2 epitope presenting virus-like particles as broad-spectrum vaccine candidates targeting cutaneous genus beta human papillomaviruses

Licensed human papillomavirus (HPV) vaccines do not target cutaneous genus beta (ß)HPV types implicated in skin cancer development in immunosuppressed individuals. The conserved N-terminus of minor capsid protein offers the opportunity to develop broad-spectrum vaccine candidates. We employed a sequential immunizatio...

Huber Bettina, Schüchner Stefan, Shafti-Keramat Saeed et al. · npj Vaccines · 0 citations

#protein folding Open access Sep 2026

A forward genetics platform for papillomavirus research

The inability to perform forward genetics has been a major barrier to human papillomavirus (HPV) research. Here, we report a platform for phenotypic selection of HPV mutants. Our method relies on large “concordant” virus libraries, where each mutant virus particle encapsidates the mutant plasmid that encodes it, thereb...

Yuka Takeo, Sydney R. Hirsch, Daniel DiMaio · Science Advances · 0 citations

Open access Sep 2026

Host cell entry and neutralisation sensitivity of H3N2 influenza A virus subclade K

Using pseudovirus particles, it is shown that subclade K-HA drives augmented entry into certain cell lines and displays significant antibody evasion, suggesting that current vaccines may provide considerable protection.

Nicole Moor, N. Chen, G. Behrens et al. · npj Vaccines · 0 citations